23 Jul, 2026
According to Straits Research, the global artemisinin combination therapy (ACT) market was valued at USD 680.15 million in 2025 and is projected to grow from USD 734.49 million in 2026 to USD 1,394.93 million by 2034, registering a CAGR of 8.35% during the forecast period (2026–2034).
Rising government initiatives for malaria elimination, growing support from international health organizations, and expanding access to affordable antimalarial medicines are key factors driving market growth.
The global artemisinin combination therapy (ACT) market is experiencing strong growth, primarily driven by the increasing prevalence of malaria in tropical and subtropical regions and the widespread adoption of artemisinin-based combination therapies (ACTs) as the standard treatment recommended by the World Health Organization (WHO). Rising government-supported malaria elimination programs, coupled with expanded access to affordable ACTs through public-private partnerships and global health organizations, are further accelerating market expansion.
However, the market faces restraints due to supply chain vulnerabilities and limited cold chain infrastructure in malaria-endemic regions, which affects the timely distribution and stability of ACT formulations. Additionally, fluctuating raw material availability from Artemisia annua cultivation poses challenges to consistent drug supply. On the other hand, several opportunities exist in the development of fixed-dose combinations that enhance treatment compliance, bioavailability, and patient outcomes. Increasing investments in pediatric formulations and collaborations for localized manufacturing in Africa and Asia are also expected to create new growth avenues for the global artemisinin combination therapy market.
North America dominated the global artemisinin combination therapy market in 2025, accounting for 40.17% of total revenue. The region's leadership is supported by strong investments in malaria research, advanced pharmaceutical manufacturing, and active participation in global health initiatives aimed at combating malaria.
Asia-Pacific is expected to register the fastest growth during the forecast period, with a CAGR of 10.34%. The region benefits from large-scale production of artemisinin, expanding pharmaceutical manufacturing capabilities, and increasing government efforts to eliminate malaria in countries such as India, China, and Vietnam.
sales@straitsresearch.com